Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Ex-Vivo Expanded Allogeneic Universal Donor TGFβi NK Cell Infusions in Combination With Temozolomide, Irinotecan, Dinutuximab, and Sargramostim in Patients With Relapsed or Refractory Neuroblastoma The STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

NCT06450041 is registered in ClinicalTrials.gov with New Approaches to Neuroblastoma Therapy Consortium as lead sponsor.

NCT NCT06450041
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06450041 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Ex-Vivo Expanded Allogeneic Universal Donor TGFβi NK Cell Infusions in Combination With Temozolomide, Irinotecan, Dinutuximab, and Sargramostim in Patients With Relapsed or Refractory Neuroblastoma The STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Phase
Phase 2
Overall status
Recruiting
Start date
December 16, 2024
Completion date
December 31, 2038
Enrollment
62 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma